Trial Profile

A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination With Subcutaneous Nivolumab

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Nivolumab (Primary) ; Hyaluronidase
Indications Carcinoma; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
Focus Pharmacokinetics
Acronyms CheckMate 76U
Sponsors Bristol-Myers Squibb

Most Recent Events

23 Feb 2023 Status changed from active, no longer recruiting to discontinued.
26 May 2021 Planned End Date changed from 7 Oct 2025 to 30 Apr 2023.
26 May 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com